Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Dec 27, 2025; 17(12): 111414
Published online Dec 27, 2025. doi: 10.4254/wjh.v17.i12.111414
Published online Dec 27, 2025. doi: 10.4254/wjh.v17.i12.111414
Severe hyperlipidemia associated with drug-induced cholestatic liver disease: A case report
Meng-Jiao Xu, Xin Wei, Yao Lu, Yao Xie, Ming-Hui Li, Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Peking University Ditan Teaching Hospital, Beijing 100015, China
Lei Sun, Department of Pathology, Beijing Ditan Hospital, Capital Medical University, Peking University Ditan Teaching Hospital, Beijing 100015, China
Ming-Hui Li, Infection, Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing 100015, China
Co-first authors: Meng-Jiao Xu and Xin Wei.
Author contributions: Xu MJ and Wei X wrote the main manuscript text and prepared Figures 1 and 2, and they contributed equally to this manuscript as co-first authors; Lu Y, Xie Y, and Li MH approved the submitted version after modification; Sun L prepared Figure 3; Xie Y and Li MH edited the manuscript. All authors made a significant contribution to the work reported. All authors have read and approved the final manuscript.
Supported by Beijing Municipal Health Commission High-Level Public Health Technical Personnel Construction Project, No. discipline leader-03-26; Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support, No. ZLRK202301; Beijing Hospitals Authority “Peak” Talent Training Program, No. DFL20241803; and The National Key Research and Development Program, No. 2023YFC2306901 and No. 2023YFC2308105.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ming-Hui Li, Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Peking University Ditan Teaching Hospital, No. 8 Jingshun East Street, Chaoyang District, Beijing 100015, China. wuhm2000@sina.com
Received: July 3, 2025
Revised: August 11, 2025
Accepted: November 21, 2025
Published online: December 27, 2025
Processing time: 180 Days and 19.5 Hours
Revised: August 11, 2025
Accepted: November 21, 2025
Published online: December 27, 2025
Processing time: 180 Days and 19.5 Hours
Core Tip
Core Tip: Hyperlipidemia is closely associated with the development of multiple diseases and is widely recognized as a major risk factor for cardiovascular disease. In clinical settings, drug-induced cholestatic liver disease can increase blood cholesterol and triglyceride levels, a condition known as secondary hyperlipidemia. Furthermore, lipid overload can ex